Clinical Trial Update: A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 clinical trial investigating Eloralintide (LY3841136) in adults who are overweight or obese with Type 2 diabetes, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight
• Type 2 Diabetes Mellitus

Drugs mentioned

• Eloralintide (LY3841136)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Overweight, Obesity | Phase 3 | Status: RECRUITING